Physician profile
Brian R Bonfardin
NPI 1356322515
$2,627,588.97
in general payments reported to CMS, 2019-2025
23 companies · $769K in 2025
The $769K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149K · 2020: $144K · 2021: $267K · 2022: $339K · 2023: $377K · 2024: $583K · 2025: $769K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.4M · Travel and Lodging: $134K · Honoraria: $106K · Consulting Fee: $96K · Food and Beverage: $33K · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,358,734.50 |
| Travel and Lodging | $134,267.90 |
| Honoraria | $106,300.00 |
| Consulting Fee | $96,275.00 |
| Food and Beverage | $32,798.79 |
| Education | $113.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $604,399.66 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $489,135.79 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $481,177.04 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $368,028.03 | 2020-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $197,551.59 | 2019-2021 | |
| Axsome Therapeutics, INC. | $177,157.28 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $122,312.35 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $114,562.09 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $39,849.38 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $28,446.12 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $2,212.08 | 2019-2023 | Spravato |
| Sunovion Pharmaceuticals INC. | $2,007.44 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $375.30 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Lundbeck LLC | $155.34 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $63.51 | 2019-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $42.14 | 2019 | |
| Idorsia Pharmaceuticals US INC | $29.87 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $16.88 | 2019 | |
| Almatica Pharma LLC | $14.48 | 2022 | |
| Neuronetics, INC. | $14.03 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.77 | 2019 | |
| Bausch Health US, LLC | $13.30 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bonfardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.